The Novitas Team

Paul J. Schmitt

Managing Director

610-254-4286 pschmitt@novitascapital.com

 

Paul Schmitt has served as Managing Director of Novitas Capital in Wayne, Pennsylvania since 1999. As Managing Director, he oversees Novitas Capital’s interests in early stage life sciences companies. In May of 2009, Mr. Schmitt assumed an additional role of Acting CEO of Amorcyte, a Novitas portfolio company, developing cell therapies for Cardiovascular Disease and AMI.

 

In October 2011, Amorcyte was sold to Neostem (AMEX:NBS) for total proceeds of $18Million plus 30% of all revenues resulting from any strategic partnerships or licensing agreements.

Prior to the formation of Novitas, Mr. Schmitt spent 23 years as CEO of 4 different life science companies whose commercial businesses encompassed medical devices, biotechnology and pre-clinical and clinical drug development services. Growth in all 4 companies was achieved largely through new product development; commercialization of early stage technologies sourced from universities, corporate acquisitions, and funded corporate partnerships. During his career Mr. Schmitt has directly raised in excess of $500 Million from venture financings, IPO’s and strategic partnerships.

 

Prior to Novitas, Mr. Schmitt was most recently Chairman, President and Chief Executive Officer of Chrysalis International Corporation (NASDAQ: CRLS).  Chrysalis was formed in 1996 through the merger of DNX Corporation (NASDAQ: DNXX) and BioClin International.  Chrysalis was a leading supplier of pre-clinical and clinical drug development services, including the utilization of transgenic animal science technologies to identify and validate new human genetic targets of disease emerging from worldwide genomic initiatives.

 

Page: 1 2